Prime Medicine (NYSE:PRME – Get Free Report) and Qiagen (NYSE:QGEN – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.
Analyst Ratings
This is a summary of recent recommendations for Prime Medicine and Qiagen, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Prime Medicine | 0 | 0 | 9 | 1 | 3.10 |
| Qiagen | 0 | 7 | 3 | 0 | 2.30 |
Prime Medicine currently has a consensus price target of $13.13, indicating a potential upside of 343.41%. Qiagen has a consensus price target of $47.71, indicating a potential upside of 20.73%. Given Prime Medicine’s stronger consensus rating and higher probable upside, analysts clearly believe Prime Medicine is more favorable than Qiagen.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Prime Medicine | $800,000.00 | 485.30 | -$198.13 million | ($2.05) | -1.44 |
| Qiagen | $1.98 billion | 4.43 | $83.59 million | $0.36 | 110.03 |
Qiagen has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Prime Medicine and Qiagen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Prime Medicine | N/A | -107.87% | -74.97% |
| Qiagen | 4.23% | 13.92% | 8.40% |
Insider & Institutional Ownership
70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 23.5% of Prime Medicine shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Risk and Volatility
Prime Medicine has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500.
Summary
Prime Medicine beats Qiagen on 8 of the 15 factors compared between the two stocks.
About Prime Medicine
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.
About Qiagen
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.
Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
